688 | INTRAVENOUS MIDDLE‐DOSE METHOTREXATE INCORPORATED INTO R‐CHOP PREVENTED CENTRAL NERVOUS SYSTEM RELAPSE IN HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS

Documenti analoghi

• 704 | ORELABRUTINIB PLUS RITUXIMAB AND HIGH‐DOSE METHOTREXATE IN PRIMARY CENTRAL NERVOUS SYSTEM DIFFUSED LARGE B‐CELL LYMPHOMA: A SINGLE‐ARM PHASE II STUDY
  di: F. Zhu, et al.
  Pubblicazione: (2025)
• 307 | IMPACT OF CELL OF ORIGIN, GENE REARRANGEMENTS, FRONTLINE TREATMENT ON INCIDENCE OF CENTRAL NERVOUS SYSTEM LYMPHOMA RELAPSE IN NEWLY DIAGNOSED LARGE B‐CELL LYMPHOMA
  di: A. S. Falade, et al.
  Pubblicazione: (2025)
• 695 | CLINICAL RESPONSE AND SAFETY FOR RELAPSED/REFRACTORY CENTRAL NERVOUS SYSTEM DIFFUSE LARGE B CELL LYMPHOMA TREATED BY RADIOTHERAPY SEQUENTIAL GLOFITMAB
  di: J. Huang, et al.
  Pubblicazione: (2025)
• 472 | THE HETEROGENEITY AND RELATED PROGNOSTIC FACTORS OF PRIMARY CENTRAL NERVOUS SYSTEM DIFFUSE LARGE B‐CELL LYMPHOMA BASED ON SINGLE‐CELL SEQUENCING TECHNOLOGY
  di: J. Youchao, et al.
  Pubblicazione: (2025)
• 281 | LONG‐TERM RESULTS FROM EPCORE NHL‐2: FIXED‐DURATION EPCORITAMAB + R‐CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA WITH HIGH‐RISK FEATURES
  di: L. Falchi, et al.
  Pubblicazione: (2025)